Methylin is owned by Specgx Llc.
Methylin contains Methylphenidate Hydrochloride.
Methylin has a total of 1 drug patent out of which 0 drug patents have expired.
Methylin was authorised for market use on 19 December, 2002.
Methylin is available in solution;oral dosage forms.
The generics of Methylin are possible to be released after 07 October, 2024.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7691880 | SPECGX LLC | Methylphenidate solution and associated methods of administration and production |
Oct, 2024
(1 year, 7 months from now) |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: SOLUTION;ORAL
3
United States
1
China
1
Austria
1
Australia
1
Spain
1
Canada
1
Mexico
1
Japan
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic